# A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

> **NCT02372227** · PHASE1 · TERMINATED · sponsor: **Verastem, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Relapsed Malignant Mesothelioma

## Interventions

- **DRUG:** VS-5584 and VS-6063

## Key facts

- **NCT ID:** NCT02372227
- **Lead sponsor:** Verastem, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02372227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02372227, "A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02372227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*